<DOC>
	<DOCNO>NCT00466258</DOCNO>
	<brief_summary>Main objective : - To evaluate applicability treatment : 1 . To evaluate treatment toxicity accord Common Terminology Criteria ( CTC ) version 3.0 National Cancer Institute ( NCI ) . 2 . To evaluate opportunistic non-opportunistic infection 6 cycle treatment rituximab plus cyclophosphamide , doxorubicin , vincristine , prednisone ( R-CHOP ) administer every 14 day highly active antiretroviral therapy ( HAART ) patient diffuse large B cell lymphoma ( DLBCL ) HIV infection . 3 . To evaluate adherence treatment 6 cycle R-CHOP consider delay administration cycle reduction dos chemotherapy ( plan dose administer predicted term ) . Secondary objective : - To evaluate efficacy treatment patient DLBCL HIV infection 6 cycle treatment R-CHOP administer every 14 day ( R-CHOP/14 ) : 1 . To determine global response complete remission tax . 2 . To evaluate duration response . 3 . To evaluate probability event-free survival 5 year . 4 . To evaluate probability global survival 5 year . - To identify predictive factor response 6 cycle treatment R-CHOP administer every 14 day patient DLBCL HIV infection . - To evaluate impact therapeutic combination R-CHOP HAART parameter HIV infection ( HIV viral load CD4+ lymphocyte count ) .</brief_summary>
	<brief_title>LINFOTARGAM : Treatment With Chemotherapy Plus Rituximab Highly Active Antiretroviral Therapy Patients With Diffuse Large B Cell Lymphoma Infection With Human Immunodeficiency Virus ( HIV )</brief_title>
	<detailed_description>This clinical trial pharmaceutical drug use condition authorization .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Patients HIV infection diagnose DLBCL stage ( IIV accord Ann Arbor classification ) previously treat lymphoma . Patients CD20positive diffuse large Bcell lymphoma Aged 18 70 year old Any score International Prognostic Index . ( It also applicable patient nonHodgkin lymphoma [ NHL ] infect HIV . ) ECOG performance status 0 3 Written inform consent Absolute neutrophil count &gt; 1.5 x 10^9/L . Absence synchronic nonsynchronic neoplasia exception nonmelanoma skin tumor situ cervical carcinoma . CD4+ lymphocyte count &gt; 100/µL Patients diffuse large B cell lymphoma previously treat . Patients primary central nervous system lymphoma . Patients Burkitt Burkittlike NHL . CD4+ lymphocyte count &lt; 100/µL Opportunistic infection AIDSrelated neoplasias activity . Active drugaddiction . Pregnant lactate woman adult fertile age use effective contraceptive method . Patients serious alter renal function ( creatinine &gt; 2.5 x upper limit normal [ ULN ] ) hepatic [ bilirubin , ALT AST &gt; 2.5 x ULN ] , except investigator suspect cause disease . Cardiac insufficiency ejection fraction &lt; 40 % Patients serious psychiatric disease interfere capacity understand study ( include alcoholism active drugaddiction ) . ECOG &gt; 3 Patients know hypersensitivity murine protein component study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Diffuse large B cell lymphoma</keyword>
	<keyword>HIV</keyword>
	<keyword>R-CHOP</keyword>
	<keyword>Highly active antiretroviral therapy</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>